Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Diabetologia
|
November 19, 2015
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Michael A Nauck, Murray W Stewart, Christopher Perkins, et al.
Diabetes Care
|
October 20, 2007
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
Julio Rosenstock, James E Foley, Marc Rendell, et al.
Familial Cancer
|
October 27, 2017
Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge
Henry T Lynch, Stephen Lanspa, Trudy Shaw, et al.
Diabetes Research and Clinical Practice
|
July 7, 2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
Philip D Home, Bo Ahrén, Jane E B Reusch, et al.
International Journal of Cancer
|
December 7, 2015
Screening for familial and hereditary prostate cancer
Henry T Lynch, Omofolasade Kosoko-Lasaki, Stephen W Leslie, et al.
Diabetes Care
|
June 8, 2015
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, et al.
Cancer Research
|
April 11, 2019
Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers
Candace D Middlebrooks, Mark L Stacey, Qing Li, et al.
Diabetes, Obesity & Metabolism
|
April 1, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study
Elena A Christofides, Orlando Puente, Paul Norwood, et al.
AIDS Reviews
|
February 8, 2021
The Importance of Understanding the Stages of COVID-19 in Treatment and Trials
Daniel O Griffin, Denise Brennan-Rieder, Binh Ngo, et al.
Expert Opinion on Investigational Drugs
|
March 15, 2021
The time to offer treatments for COVID-19
Binh T Ngo, Paul Marik, Pierre Kory, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Diabetologia
|
November 19, 2015
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Michael A Nauck, Murray W Stewart, Christopher Perkins, et al.
Diabetes Care
|
October 20, 2007
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
Julio Rosenstock, James E Foley, Marc Rendell, et al.
Familial Cancer
|
October 27, 2017
Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge
Henry T Lynch, Stephen Lanspa, Trudy Shaw, et al.
Diabetes Research and Clinical Practice
|
July 7, 2017
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
Philip D Home, Bo Ahrén, Jane E B Reusch, et al.
International Journal of Cancer
|
December 7, 2015
Screening for familial and hereditary prostate cancer
Henry T Lynch, Omofolasade Kosoko-Lasaki, Stephen W Leslie, et al.
Diabetes Care
|
June 8, 2015
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, et al.
Cancer Research
|
April 11, 2019
Analysis of the <i>CDKN2A</i> Gene in FAMMM Syndrome Families Reveals Early Age of Onset for Additional Syndromic Cancers
Candace D Middlebrooks, Mark L Stacey, Qing Li, et al.
Diabetes, Obesity & Metabolism
|
April 1, 2024
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study
Elena A Christofides, Orlando Puente, Paul Norwood, et al.
AIDS Reviews
|
February 8, 2021
The Importance of Understanding the Stages of COVID-19 in Treatment and Trials
Daniel O Griffin, Denise Brennan-Rieder, Binh Ngo, et al.
Expert Opinion on Investigational Drugs
|
March 15, 2021
The time to offer treatments for COVID-19
Binh T Ngo, Paul Marik, Pierre Kory, et al.
Page
of 5